Eui-Soon Kim

Dr. Eui-Soon Kim

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Science Immunology
Verified
Journal Article
Closed access
YLYong Joon Lee
Yong Joon Lee
JKJee Ye Kim
Jee Ye Kim
SJSeung Hyuck Jeon
Seung Hyuck Jeon
HNHeejin Nam
Heejin Nam
JJJae Hyung Jung
Jae Hyung Jung
ESEui-Cheol Shin
Eui-Cheol Shin
Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune response in breast cancer, we examined the heterogeneity of CD8 + T cells in tumors, metastatic lymph nodes (mLNs), and peripheral blood from patients with early breast cancer ( n = 131). Among tissue-resident memory CD8 + T (T RM ) cells, including virus- and tumor-specific CD8 + T cells, CD39 expression was observed in a tumor-specific and exhausted subpopulation in both tumors and mLNs. CD39 + T RM cells from tumors and mLNs exhibited a phenotypic similarity and clonally overlapped with each other. Moreover, tumor or mLN CD39 + T RM cells clonally overlapped with CD39 − T RM and non-T RM cells in the same compartment, implying a tissue-specific differentiation process. These inter-subpopulationally overlapping CD39 + T RM clonotypes were frequently detected among effector memory CD8 + T cells in peripheral blood, suggesting a systemic clonal overlap. CD39 + T RM cell enrichment was heterogeneous among molecular subtypes of breast cancer, which is associated with the different role of antitumor immune responses in each subtype. In vitro blockade of PD-1 and/or CTLA-4 effectively restored proliferation of CD39 + T RM cells and enhanced cytokine production by CD8 + T cells from tumors or mLNs, particularly in the presence of CD39 + T RM enrichment. This suggests that CD39 + T RM cells have a capacity for functional restoration upon ICI treatment. Thus, our study indicates that CD39 + T RM cells with a clonal overlap across compartments are key players in antitumor immunity in breast cancer.

30 January 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SJSeung Hyuck Jeon
Seung Hyuck Jeon
MKMinyong Kang
Minyong Kang
MJMinwoo Jeon
Minwoo Jeon
YCYouseung Chung
Youseung Chung
AKA Reum Kim
A Reum Kim
SPSu-Hyung Park
Su-Hyung Park
Purpose: Regulatory T cells (Tregs) exert immunosuppressive functions and hamper antitumor immune responses in the tumor microenvironment. Understanding the heterogeneity of intratumoral Tregs, and how it changes with tumor progression, will provide clues regarding novel target molecules of Treg-directed therapies. Experimental Design: From 42 patients with renal cell carcinoma and 5 patients with ovarian cancer, immune cells from tumor and peripheral blood were isolated. We performed multicolor flow cytometry and RNA-sequencing to characterize the phenotypes and heterogeneity of intratumoral Tregs. In vitro functional assays were performed to evaluate suppressive capacity of Tregs and effect of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)-mediated depletion. The CT26 tumor model was used to evaluate the association between intratumoral Tregs and tumor growth, and examine the in vivo role of CEACAM1+ intratumoral Tregs on antitumor immunity. Results: We found that CEACAM1 was selectively expressed on intratumoral Tregs, whereas its expression on peripheral Tregs or other immune cells was low. The CEACAM1+ intratumoral Tregs accumulated with tumor progression, whereas the CEACAM1− subset did not. Notably, we found that CEACAM1 marked intratumoral Tregs that exhibited highly suppressive and activated phenotypes with substantial clonal expansion. Depletion of CEACAM1-expressing cells from tumor-infiltrating leukocytes led to increased effector functions of tumor-infiltrating T cells. Moreover, CEACAM1+ cell depletion further enhanced anti-PD-1–mediated reinvigoration of exhausted CD8+ T cells. Conclusions: CEACAM1 marks highly suppressive subset of intratumoral Tregs, and can be a target for selective depletion of intratumoral Tregs. These results may inform future studies on CEACAM1-mediated depletion in patients with cancer.

1 January 2020 in Cardiovascular Prevention and Pharmacotherapy
Verified
Journal Article
Open access
PDF file
EKEui-Soon Kim
Eui-Soon Kim
JYJong-Chan Youn
Jong-Chan Youn
SBSang Hong Baek
Sang Hong Baek

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
EKEui-Soon Kim
Eui-Soon Kim
SPSun-Kyeong Park
Sun-Kyeong Park
JYJong-Chan Youn
Jong-Chan Youn
HLHye Sun Lee
Hye Sun Lee
HYHan Young Yu
Han Young Yu
SBSang Hong Baek
Sang Hong Baek
Kim ES, et al. J Korean Med Sci. 2023 Dec;39(1):e8. https://doi.org/10.3346/jkms.2024.39.e8

27 February 2024 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
EKEui-Soon Kim
Eui-Soon Kim
SPSun-Kyeong Park
Sun-Kyeong Park
DCDaniel Sung-Ho Cho
Daniel Sung-Ho Cho
JYJong-Chan Youn
Jong-Chan Youn
HLHye Sun Lee
Hye Sun Lee
SBSang Hong Baek
Sang Hong Baek

20 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SJSeung Hyuck Jeon
Seung Hyuck Jeon
KSKoung Jin Suh
Koung Jin Suh
SJSungmin Jung
Sungmin Jung
MJMinwoo Jeon
Minwoo Jeon
HJHo Cheol Jang
Ho Cheol Jang
ESEui-Cheol Shin
Eui-Cheol Shin
Purpose: PD-1/PD-L1 blockade modulates the responses of T cells, including regulatory T cells (Treg). Understanding the changes of Treg upon PD-1/PD-L1 blockade in patients with cancer and their association with therapeutic response will provide clues about the mechanisms underlying resistance to treatment. Experimental Design: Peripheral blood samples were acquired before and at 1 week following treatment from 65 patients [triple-negative (TN), n = 35; luminal, n = 30] enrolled in the KORNELIA phase II trial, which evaluated the efficacy of chemoimmunotherapy combining nivolumab and eribulin in patients with HER2-negative breast cancer. The immunophenotype of circulating immune cells was analyzed by flow cytometry. T-cell receptor sequencing was used to track the clonotypes of circulating Treg in relation to the tumor-related clonotypes. Results: In both breast cancer subtypes, chemoimmunotherapy increased the proportion of circulating Treg as well as their proliferative response. Notably, we observed an increased frequency of the circulating Treg population with tumor-related clonotypes after treatment in triple-negative breast cancer (TNBC). Moreover, increased proliferation of circulating Treg was associated with poor response to treatment, only in TNBC. This association between circulating Treg proliferation and poor clinical response was further supported by the analysis of publicly available single-cell transcriptomic data from patients with TNBC. A Treg-based biomarker predicted both clinical response and survival outcomes in TNBC. Conclusions: Our results indicate that the proliferation and expansion of tumor-related clonotypes among circulating Treg are related to chemoimmunotherapy resistance, particularly in TNBC.